Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Verastem Inc (VSTM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8192)・商品コード:DATA904C8192
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:73
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-5584). Duvelisib, an oral small molecule inhibitor of PI3K-delta and PI3K-gamma in Phase 2 and Phase 3 trials, is being evaluated in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Defactinib, an oral inhibitor in Phase 1b study, is under evaluation for the treatment of pancreatic cancer, non-small cell lung cancer, mesothelioma, and ovarian cancer. Verastem’s VS-4718 and VS-5584 are being assessed for the treatment of solid tumors and lymphomas. It operates office and laboratory in Needham, Massachusetts. Verastem is headquartered in Needham, Massachusetts, the US.

Verastem Inc (VSTM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Verastem Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Verastem Inc, Medical Devices Deals, 2012 to YTD 2018 10
Verastem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Verastem Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Verastem Acquires Patent Right to Inhibition of Focal Adhesion Kinase from Encarta 12
Verastem Acquires PI3K and mTOR from S*Bio 13
Partnerships 14
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 14
Merck, Pfizer and Verastem Enter into Agreement 15
Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 16
Licensing Agreements 17
CSPC Pharmaceutical Enters into Licensing Agreement with Verastem 17
Yakult Honsha Enters into Licensing Agreement with Verastem 18
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 19
Verastem Enters Into Licensing Agreement With Scripps Research Institute For VS-4718 21
Verastem Enters into Licensing Agreement with Pfizer 23
Equity Offering 24
Verastem Plans to Raise Funds through Public Offering of Securities 24
Verastem to Raise USD43 Million in Public Offering of Shares 25
Verastem Raises USD40.2 Million in Public Offering Raise of Shares 26
Verastem Raises USD25 Million in Public Offering of Shares 28
Verastem Amends Public Offering of Shares for USD75 Million 29
Verastem USD54 Million in Public Offering of Shares 31
Verastem Raises USD35Million in Public Offering of Shares 33
Verastem Completes Public Offering Of Shares For US$63.8 Million 34
Verastem Completes IPO For US$63 Million 36
Debt Offering 38
Verastem Oncology Raises USD150 Million in Private Placement of 5% Notes Due 2048 38
Verastem Inc – Key Competitors 40
Verastem Inc – Key Employees 41
Verastem Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 08, 2018: Verastem Oncology reports second quarter 2018 financial results 43
May 03, 2018: Verastem Oncology Reports First Quarter 2018 Financial Results 46
Mar 13, 2018: Verastem Announces Year-End 2017 Financial Results 48
Nov 07, 2017: Verastem Reports Third Quarter 2017 Financial Results 50
Aug 08, 2017: Verastem Reports Second Quarter 2017 Financial Results 53
May 10, 2017: Verastem Reports First Quarter 2017 Financial Results 56
Mar 23, 2017: Verastem Reports Year-End 2016 Financial Results 58
Corporate Communications 60
Oct 18, 2018: Verastem Oncology announces executive leadership appointments and changes 60
Aug 29, 2018: Verastem Oncology names Robert E. Gagnon as chief financial officer 61
Jan 04, 2018: Verastem Appoints Joseph Lobacki as Chief Commercial Officer 62
Jul 11, 2017: Verastem Names Julie B. Feder As Chief Financial Officer 63
May 02, 2017: Verastem Appoints Eric K. Rowinsky to the Board of Directors 64
Legal and Regulatory 65
Jun 25, 2018: Verastem Oncology to join Russell 3000 index 65
Product News 66
10/11/2017: Verastem Appoints New CMO to Oversee Development of Cancer Drug Candidate Defactinib 66
Jul 25, 2017: Verastem Publishes Scientific Data Highlighting Potential Role Of FAK Inhibition In Pancreatic And Breast Cancer 67
07/25/2017: Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer 69
01/26/2017: Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer 70
Clinical Trials 72
Apr 02, 2017: Data on Verastems Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Verastem Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Verastem Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Verastem Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Verastem Inc, Medical Devices Deals, 2012 to YTD 2018 10
Verastem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Verastem Acquires Patent Right to Inhibition of Focal Adhesion Kinase from Encarta 12
Verastem Acquires PI3K and mTOR from S*Bio 13
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 14
Merck, Pfizer and Verastem Enter into Agreement 15
Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 16
CSPC Pharmaceutical Enters into Licensing Agreement with Verastem 17
Yakult Honsha Enters into Licensing Agreement with Verastem 18
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 19
Verastem Enters Into Licensing Agreement With Scripps Research Institute For VS-4718 21
Verastem Enters into Licensing Agreement with Pfizer 23
Verastem Plans to Raise Funds through Public Offering of Securities 24
Verastem to Raise USD43 Million in Public Offering of Shares 25
Verastem Raises USD40.2 Million in Public Offering Raise of Shares 26
Verastem Raises USD25 Million in Public Offering of Shares 28
Verastem Amends Public Offering of Shares for USD75 Million 29
Verastem USD54 Million in Public Offering of Shares 31
Verastem Raises USD35Million in Public Offering of Shares 33
Verastem Completes Public Offering Of Shares For US$63.8 Million 34
Verastem Completes IPO For US$63 Million 36
Verastem Oncology Raises USD150 Million in Private Placement of 5% Notes Due 2048 38
Verastem Inc, Key Competitors 40
Verastem Inc, Key Employees 41
Verastem Inc, Subsidiaries 42

List of Figures
Verastem Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Verastem Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Verastem Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8192)販売に関する免責事項を必ずご確認ください。
★調査レポート[Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆